“Key Takeaways from 2024’s Biotech IPOs – Adam Farlow Discusses with Fierce Biotech”
Is there renewed enthusiasm on the public markets for biotech companies following the uptick in IPOs seen at the start of 2024 and in the late summer and autumn? What advice would you give to biotechs considering an IPO listing? Are there key traits that define successful biotech IPOs, or red flags that signal less […]
The post “What can we learn from 2024’s biotech IPOs?” – Adam Farlow chats to Fierce Biotech appeared first on Healthcare & Life Sciences Blog.
Read More